Results 41 to 50 of about 85,599,609 (253)

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan

Drugs - Real World Outcomes
Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as a first-line therapy for type 2 diabetes in Japan. Precautions of the package inserts for ethical drugs containing DPP-4 inhibitors were revised for pemphigoid between 2016 and 2018.
Akina Takami, Gen Terashima, Takumi Tajima, Koki Yamashita, Ataru Igarashi   +4 more
doaj   +1 more source

Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis

Journal of Nepal Health Research Council, 2021
Drug-induced arthritis is not an uncommon scenario. DPP-4 inhibitors could potentially cause adverse-events mediated by cytokine-induced inflammation leading to arthritis. The activity of the DPP-4 enzyme could be inversely related to the development of
Binit Vaidya, Bhojraj Adhikari, Manisha Bhochhibhoya, Shweta Nakarmi   +3 more
doaj   +1 more source

Battery‐Inspired Electrochemical Synapses for Neuromorphic Applications

Advanced Science, EarlyView.
Battery‐ion‐inspired synaptic devices integrate diverse electrolyte systems (solid, ion‐gel, liquid) with transition metal oxides, two‐dimensional materials, and organic channels to regulate ion‐electron coupling. By tailoring ion transport and host interactions, these platforms enable controllable plasticity and energy‐efficient implementations for ...
Won Woo Lee, SeongCheol Jang, Wangmyung Choi, Jaewon Park, Jaehyun Hur, Hocheon Yoo, Hyun‐Suk Kim   +6 more
wiley   +1 more source

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

Diabetes, Metabolic Syndrome and Obesity, 2020
Takeshi Osonoi, Miyoko Saito, Naoya Koda, Satako Douguchi, Takako Nakano, Kensuke Ofuchi, Makoto Katoh Naka Kinen Clinic, Ibaraki, JapanCorrespondence: Makoto KatohNaka Kinen Clinic, 745-5 Nakadai, Naka-Shi, Ibaraki 311-0113, JapanTel +81-29-353-2800Fax +
Osonoi T, Saito M, Koda N, Douguchi S, Nakano T, Ofuchi K, Katoh M   +6 more
doaj  

Clinical Use of DPP-4 Inhibitors

Frontiers in Endocrinology, 2019
DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk.
Baptist Gallwitz
doaj   +1 more source

DPP-4 inhibitors subgroup analysis.

, 2019
DPP-4 inhibitors subgroup analysis.
Li-Jiuan Shen (1447438), Chih-Fen Huang (5007860), Fei-Yuan Hsiao (2212222), Tzu-Lan Huang (6718856), Chih-Kang Chiang (135324)   +4 more
core   +1 more source

An Avalanche Effect Nanomodulator Triggers Cascade Ferroptosis/Cuproptosis for Immunosuppressive Microenvironment Remodeling

Advanced Science, EarlyView.
A nanomodulator called L‐Arginine/lificiguat@Copper‐hollow Prussian blue@Calcium phosphate nanoparticles is constructed to launch a self‐amplifying “avalanche effect” in tumor cells. The ensuing cascade, triggered by the acidic tumor microenvironment and near‐infrared light, induces calcium overload, generates a reactive oxygen species and reactive ...
Hongmei Zhou, Caixi Yu, Guilan Xu, Lijuan Liu, Yujia Liang, Yulin Liang, He Ding, Litu Zhang, Piaoping Yang, Chen Wang   +9 more
wiley   +1 more source

Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects

Molecular Metabolism, 2017
Objective: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) possess multiple bioactive isoforms that are rendered non-insulinotropic by the enzyme dipeptidyl peptidase-4 (DPP-4).
Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda, Jun Honjo, Hidemitsu Sakagami, Hiroya Kitsunai, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Timothy J. Kieffer, Masakazu Haneda   +10 more
doaj   +1 more source

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure [PDF]

, 2011
Background Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half ...
Rudolf A de Boer, Maxi Meissner, van Gilst Wiek H, Wiek H van Gilst, de Boer, Rudolf A., Yin Meimei, de Boer Rudolf A, Sillje, Herman H. W., van Gilst, Wiek H., Meimei Yin, Meissner Maxi, Silljé Herman HW, Yin, Meimei, Herman HW Silljé, Meissner, Maxi   +14 more
core   +1 more source

Dual‐line Genome‐scale CRISPR Screening Enables Robust Target Gene Discovery

Advanced Science, EarlyView.
A species‐optimized CRISPR platform integrates efficient piggyBac delivery, genome‐scale sgRNA libraries, and parallel screening in two independently engineered Bactrocera dorsalis Cas9 cell lines. Cross‐line consensus analysis filters line‐specific effects, enriches candidates with reproducible in vivo phenotypes, and reveals conserved, species ...
Ziniu Li, Jiao Qiao, Qiuyuan Zhang, Peipei Liu, Chenjun Zheng, Qi Zhou, Mengqi Ji, Zhihui Zhu, Xiaoxue Li, Hongyu Zhang   +9 more
wiley   +1 more source